Trending News

Moderna has released results from in vitro neutralisation studies of sera from individuals vaccinated with its COVID-19 vaccine showing activity against emerging strains of SARS-CoV-2. Vaccination with the Moderna COVID-19 vaccine produced neutralising titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and Republic of South Africa, respectively. […]

Novavax, the late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, has finalised an agreement with the government of Canada to supply up to 76 million doses of NVX-CoV2373, the company’s recombinant protein-based COVID-19 vaccine. Canada has committed to purchase 52 million doses of the vaccine with the option for up to an additional […]

NovAliX, a drug discovery-focused contract research organisation (CRO), and Chemical.AI, an artificial intelligence (AI) company leveraging human expertise and cutting-edge AI technology for chemistry and pharmaceuticals, have created a strategic It is hoped that the affiliation will help create the most relevant AI solutions for drug developers. NovAliX brings 20 years of industry experience and […]

Swissmedic, the Swiss Agency for Therapeutic Products, has authorised the COVID-19 Moderna Vaccine in Switzerland. The authorisation is given according to the ordinary approvals procedure and is based on a rolling submission of data and the totality of scientific evidence shared by the company, including a data analysis from the pivotal Phase 3 clinical study […]

The COVID-19 vaccine developed by Moderna has been given regulatory approval for supply by the Medicines and Healthcare products Regulatory Agency (MHRA). This follows a thorough and rigorous assessment by the MHRA’s teams of scientists, including advice from the independent Commission on Human Medicines, which reviewed in depth all the data to ensure this vaccine […]

Novavax has executed an Advance Purchase Agreement with the Commonwealth of Australia for 51 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. This follows an agreement in principle that was announced in November 2020. NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. Novavax is currently conducting late-stage […]

The European Commission has granted a conditional marketing authorisation (CMA) for Moderna’s COVID-19 vaccine Moderna, allowing vaccination programs using the Moderna vaccine to be rolled out across the European Union. The authorisation is based upon the recommendation of the European Medicines Agency (EMA) for use of the COVID-19 Vaccine Moderna for active immunization to prevent […]

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has provided authorisation for emergency supply of the Oxford University AstraZeneca COVID-19 vaccine for the active immunisation of individuals 18 years or older. The authorisation recommends two doses administered with an interval of between four and 12 weeks. This regimen was shown in clinical trials to be […]

The UK government has accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK. The Joint Committee on Vaccination and Immunisation (JCVI) will also publish its latest advice for the priority groups to receive this vaccine, with this announcement […]

LSBio, a provider of antibodies and life science research reagents, has acquired UK-based Absolute Antibody, its sister company Kerafast. LSBio provides IHC-validated reagent antibodies and services to the global community of academic, pharmaceutical and biotech researchers. The company has built a catalogue of more than 750,000 reagent antibodies, assay kits, proteins, and biochemicals, and its […]